The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
 
Frede Donskov
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Eric Voog
No Relationships to Disclose
 
Elizabeth J. Hovey
Consulting or Advisory Role - Amgen; Janssen
 
Carsten Grüllich
Research Funding - Novartis
Travel, Accommodations, Expenses - Pfizer
 
Louise M. Nott
No Relationships to Disclose
 
Katharine Ellen Cuff
Honoraria - Roche
Consulting or Advisory Role - Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Roche
 
Thierry Gil
No Relationships to Disclose
 
Niels Viggo Jensen
No Relationships to Disclose
 
Christine Chevreau
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
 
Sylvie Negrier
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Reinhard Depenbusch
No Relationships to Disclose
 
Lothar Bergmann
No Relationships to Disclose
 
Izzy Cornelio
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Anne Champsaur
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Bernard J. Escudier
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Exelixis; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Thomas Powles
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy